Telehealth Monitoring in Inflammatory Bowel Disease: Effects on Medication Compliance, Self-Efficacy, and Quality of Life

NCT ID: NCT06971627

Last Updated: 2025-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-20

Study Completion Date

2025-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized controlled trial aims to evaluate the effect of nurse-led telehealth monitoring on medication adherence, self-efficacy, and quality of life in individuals with inflammatory bowel disease (IBD). The study will be conducted at the IBD Outpatient Clinic of Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty. Participants will be randomly assigned to either an intervention group receiving a 3-month structured telehealth program (including education, counseling, phone calls, and reminders) or a control group receiving only standard care and an educational booklet. Outcomes will be assessed at baseline and after 12 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized controlled trial aims to assess the impact of a nurse-led telehealth monitoring program on medication adherence, self-efficacy, and quality of life in patients with inflammatory bowel disease (IBD). The study will be conducted at the IBD Outpatient Clinic, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital.

Participants will be randomly assigned to either an intervention or control group. The intervention group will receive a 12-week structured telehealth program including an educational booklet, video content, a Zoom-based group session, biweekly phone calls, and reminder messages. The control group will receive only standard care and the educational booklet, with no additional intervention.

Assessments will be conducted at baseline (Week 0) and at the end of the intervention (Week 12) using validated tools: Harvey-Bradshaw Index (HBI), Simple Clinical Colitis Activity Index (SCCAI), Medication Adherence Report Scale (MARS), MedTake Test, IBD Self-Efficacy Scale, IBD Quality of Life Questionnaire, and IBD Distress Scale.

The effectiveness of the intervention will be determined by comparing pre- and post-intervention outcomes between the two groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease (IBD) Medication Compliance Quality of Life Telehealth Monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study is designed as a randomized controlled trial with a pretest-posttest design, consisting of two groups: an intervention group and a control group.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants
Single

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.

Group Type EXPERIMENTAL

Nurse-led Telehealth Monitoring Program

Intervention Type BEHAVIORAL

Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.

Control group

Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.

Group Type OTHER

No intervention

Intervention Type OTHER

Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nurse-led Telehealth Monitoring Program

Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.

Intervention Type BEHAVIORAL

No intervention

Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals aged 18 years or older
* Individuals aged 18 years or older
* Able to read and write in Turkish
* Diagnosed with inflammatory bowel disease (IBD) for at least 6 months
* In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3)
* Able to use a smartphone
* Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address
* Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom)
* Willing to participate in the study voluntarily

Exclusion Criteria

* Diagnosed with any psychiatric or cognitive disorder
* Having any condition that impairs communication
* Pregnant women
* Patients receiving infusion-based treatment
* Having an advanced chronic disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul University - Cerrahpasa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zeliha Tülek

RN, MSc, PhD, Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kimya Kılıçaslan, PhD Candidate

Role: PRINCIPAL_INVESTIGATOR

Istanbul University - Cerrahpasa Institute of Graudate Studies

Zeliha Tulek, PhD, Prof.

Role: STUDY_DIRECTOR

Istanbul University - Cerrahpasa, Florence Nightingale Faculty of Nursing

Aykut Ferhat Çelik, MD, Prof.

Role: STUDY_CHAIR

Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kimya Kılıçaslan, PhD Candidate

Role: CONTACT

+90 535 083 45 53

Zeliha Tulek, PhD, Prof.

Role: CONTACT

+90 532 776 29 93

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kimya Kılıçaslan, RN, PhD Candidate

Role: primary

+90 535 083 45 53

References

Explore related publications, articles, or registry entries linked to this study.

Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK. Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Syst Rev. 2023 May 4;5(5):CD014821. doi: 10.1002/14651858.CD014821.pub2.

Reference Type BACKGROUND
PMID: 37140025 (View on PubMed)

Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res. 2022 Mar 24;24(3):e28978. doi: 10.2196/28978.

Reference Type BACKGROUND
PMID: 35323120 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Inflammatory Bowel Disease

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Telemonitoring for IBD Goodness Examination in Russia
NCT05994716 ENROLLING_BY_INVITATION NA
TOD-IBD: Empowering Patients On-Demand
NCT06179563 ENROLLING_BY_INVITATION NA